FOLH1 and neoplasm: Initial reports suggest that pretherapeutic PET data in terms of SUVmax values correlate with absorbed tumor dose and changes in terms of decreasing SUVmax values in patients receiving either 177Lu-PSMA-I&T [134] or 177Lu-PSMA-617 [118], emphasizing also the need of PSMA ligand PET imaging for patient selection.